RAD51AP1 Promotes Progression of Ovarian Cancer Via TGF-β/Smad Signalling Pathway

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2020 Dec 14

PMID 33314567

Citations 17

Authors

Hongyu Zhao

Yan Gao

Qi Chen

Jie Li

Meng Ren

Xiaoting Zhao

Wentao Yue

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OC) is one of the leading causes of female deaths. However, the molecular pathogenesis of OC has still remained elusive. This study aimed to explore the potential genes associated with the progression of OC. In the current study, 3 data sets of OC were downloaded from the GEO database to identify hub gene. Somatic mutation data obtained from TCGA were used to analyse the mutation. Immune cells were used to estimate effect of the hub gene to the tumour microenvironment. RNA-seq and clinical data of OC patients retrieved from TCGA were used to investigate the diagnostic and prognostic values of hub gene. A series of in vitro assays were performed to indicate the function of hub gene and its possible mechanisms in OC. As a result, RAD51AP1 was found as a hub gene, which expression higher was mainly associated with poor survival in OC patients. Up-regulation of RAD51AP1 was closely associated with mutations. RAD51AP1 up-regulation accompanied by accumulated Th2 cells, but reduced CD4 + T cells and CD8 + T cells. Nomogram demonstrated RAD51AP1 increased the accuracy of the model. Down-regulation of RAD51AP1 suppressed proliferation, migration and invasion capabilities of OC cells in vitro. Additionally, scatter plots showed that RAD51AP1 was positively correlated with genes in TGF-β/Smad pathway. The above-mentioned results were validated by RT-qPCR and Western blotting. In conclusion, up-regulation of RAD51AP1 was closely associated with mutations in OC. RAD51AP1 might represent an indicator for predicting OS of OC patients. Besides, RAD51AP1 might accelerate progression of OC by TGF-β/Smad signalling pathway.

Citing Articles

Identification of RAD51AP1 as a key gene in hepatitis B virus-associated hepatocellular carcinoma.

Wan M, Wang Y, Liu X, Li Y, Deng C, Sun C Heliyon. 2025; 11(1):e41594.

PMID: 39850418 PMC: 11755046. DOI: 10.1016/j.heliyon.2024.e41594.

KMT2A facilitates the epithelial-to-mesenchymal transition and the progression of ovarian cancer.

Zhu Y, Jiang S, Tang R, Chen H, Jia G, Zhou X Mol Cell Biochem. 2024; .

PMID: 39589456 DOI: 10.1007/s11010-024-05167-x.

Knocking down RAD51AP1 enhances chemosensitivity by inhibiting the self-renewal of CD133 positive ovarian cancer stem-like cells.

Zeng S, Yan Z, Ren Q, Lin L, Chen Z Discov Oncol. 2024; 15(1):410.

PMID: 39235706 PMC: 11377390. DOI: 10.1007/s12672-024-01258-9.

[Research Advances of RAD51AP1 in Tumor Progression and Drug Resistance].

Liu R, Li M, Hu Z, Song Z, Chen J Zhongguo Fei Ai Za Zhi. 2023; 26(9):701-708.

PMID: 37985156 PMC: 10600754. DOI: 10.3779/j.issn.1009-3419.2023.102.34.

Wei Y, Lan C, Wang X, Zhou X, Liao X, Huang H Int J Gen Med. 2023; 16:4377-4392.

PMID: 37789880 PMC: 10543100. DOI: 10.2147/IJGM.S431206.

References

Wu Y, Wang H, Qiao L, Jin X, Dong H, Wang Y . Silencing of RAD51AP1 suppresses epithelial-mesenchymal transition and metastasis in non-small cell lung cancer. Thorac Cancer. 2019; 10(9):1748-1763. PMC: 6718026. DOI: 10.1111/1759-7714.13124. View

Zhao H, Gao Y, Chen Q, Li J, Ren M, Zhao X . RAD51AP1 promotes progression of ovarian cancer via TGF-β/Smad signalling pathway. J Cell Mol Med. 2020; 25(4):1927-1938. PMC: 7882964. DOI: 10.1111/jcmm.15877. View

Taddei M, Giannoni E, Comito G, Chiarugi P . Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 2013; 341(1):80-96. DOI: 10.1016/j.canlet.2013.01.042. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Modesti M, Budzowska M, Baldeyron C, Demmers J, Ghirlando R, Kanaar R . RAD51AP1 is a structure-specific DNA binding protein that stimulates joint molecule formation during RAD51-mediated homologous recombination. Mol Cell. 2007; 28(3):468-81. DOI: 10.1016/j.molcel.2007.08.025. View

Kato S, Goodman A, Walavalkar V, Barkauskas D, Sharabi A, Kurzrock R . Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017; 23(15):4242-4250. PMC: 5647162. DOI: 10.1158/1078-0432.CCR-16-3133. View

Kondrashova O, Topp M, Nesic K, Lieschke E, Ho G, Harrell M . Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018; 9(1):3970. PMC: 6162272. DOI: 10.1038/s41467-018-05564-z. View

Raman A, Pohodich A, Wan Y, Yalamanchili H, Lowry W, Zoghbi H . Apparent bias toward long gene misregulation in MeCP2 syndromes disappears after controlling for baseline variations. Nat Commun. 2018; 9(1):3225. PMC: 6089998. DOI: 10.1038/s41467-018-05627-1. View

Kinoshita T, Kudo-Saito C, Muramatsu R, Fujita T, Saito M, Nagumo H . Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma. Eur J Cancer. 2017; 86:15-27. DOI: 10.1016/j.ejca.2017.08.026. View

10.

Yang S, Lheureux S, Karakasis K, Burnier J, Bruce J, Clouthier D . Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. Genome Med. 2018; 10(1):81. PMC: 6208125. DOI: 10.1186/s13073-018-0590-x. View

11.

Jayson G, Kohn E, Kitchener H, Ledermann J . Ovarian cancer. Lancet. 2014; 384(9951):1376-88. DOI: 10.1016/S0140-6736(13)62146-7. View

12.

Bence C, Hofman V, Chamorey E, Long-Mira E, Lassalle S, Albertini A . Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma. J Eur Acad Dermatol Venereol. 2019; 34(5):984-994. DOI: 10.1111/jdv.16016. View

13.

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

14.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

15.

Kumar R, Coronel L, Somalanka B, Raju A, Aning O, An O . Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018; 9(1):3931. PMC: 6158291. DOI: 10.1038/s41467-018-05805-1. View

16.

Ruan Z, Yang X, Cheng W . OCT4 accelerates tumorigenesis through activating JAK/STAT signaling in ovarian cancer side population cells. Cancer Manag Res. 2019; 11:389-399. PMC: 6314052. DOI: 10.2147/CMAR.S180418. View

17.

Chudasama P, Renner M, Straub M, Mughal S, Hutter B, Kosaloglu Z . Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma. Clin Cancer Res. 2016; 23(4):962-973. DOI: 10.1158/1078-0432.CCR-16-0860. View

18.

Siefker D, Vu L, You D, McBride A, Taylor R, Jones T . Respiratory Syncytial Virus Disease Severity Is Associated with Distinct CD8 T-Cell Profiles. Am J Respir Crit Care Med. 2019; 201(3):325-334. PMC: 6999109. DOI: 10.1164/rccm.201903-0588OC. View

19.

Pathania R, Ramachandran S, Mariappan G, Thakur P, Shi H, Choi J . Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth. Cancer Res. 2016; 76(11):3224-35. PMC: 4891240. DOI: 10.1158/0008-5472.CAN-15-2249. View

20.

Handkiewicz-Junak D, Swierniak M, Rusinek D, Oczko-Wojciechowska M, Dom G, Maenhaut C . Gene signature of the post-Chernobyl papillary thyroid cancer. Eur J Nucl Med Mol Imaging. 2016; 43(7):1267-77. PMC: 4869750. DOI: 10.1007/s00259-015-3303-3. View